Administration and Use

Information on the nasal route, administration, and prescribing of ENBUMYST.

Nasal administration provides a direct path to systemic absorption

The nasal route offers a direct path to systemic absorption without relying on the GI tract.2

The nasal cavity offers a highly vascularized mucosal surface that2:

  • Facilitates systemic drug absorption
  • Circumvents the gastrointestinal tract and hepatic first-pass metabolism

Nasal spray delivery provides a noninvasive route of administration that does not require IV access.

Icon

Administration Instructions

ENBUMYST is for nasal use only.

  • Each ENBUMYST unit is for single use and delivers 0.5 mg bumetanide upon actuation
  • Do not prime or attempt to reuse ENBUMYST for more than one administration
  • Administer ENBUMYST directly into the nose and not against the wall of the nose
  • If prescribed dose requires more than one nasal spray, alternate between right and left nostrils

Refer to the Instructions for Use for complete administration information.

Icon

How to Prescribe ENBUMYST

ENBUMYST is supplied as a 12-pack carton containing single-use nasal spray units, supporting controlled inventory and dispensing.
Medication: ENBUMYST 0.5 mg/spray (0.1 mL) nasal spray
NDC: 84388-005-12 Quantity in Billing Unit: 12 each (1 box = 12 devices)

NOTE: 12 count is sufficient to cover a 3-day treatment course and 24 count is sufficient to cover a 6-day treatment course, each at the maximum dose of 2 mg/day.


Watch how ENBUMYST is administered.

View the full Instructions for Use.

INDICATION

ENBUMYST is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome in adults.

IMPORTANT SAFETY INFORMATION

    • ENBUMYST is contraindicated in patients with anuria, hepatic coma, or a history of hypersensitivity to bumetanide, including anaphylaxis and anaphylactoid reactions.
    • ENBUMYST is a diuretic that may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, those with inadequate electrolyte intake, and the elderly. Abnormalities may include changes in blood electrolytes, BUN, glucose, and uric acid. Monitor serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid frequently during therapy.
    • Bumetanide can cause dehydration and azotemia. Discontinue bumetanide if azotemia worsens and oliguria occurs during treatment of severe progressive renal disease.
    • Tinnitus and hearing loss (usually reversible) have been reported with loop diuretics, including bumetanide. Reports indicate that ototoxicity is associated with rapid injection, severe renal impairment, use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
    • Due to potential altered absorption, avoid use in patients with significant nasal mucosal or structural abnormalities, such as acute episodes of rhinitis or congestion due to any cause.
    • Advise lactating women treated with ENBUMYST to monitor their breastfed infants for excessive urine output, dehydration, and lethargy.
    • Most common adverse reactions reported in ENBUMYST studies were hypovolemia and headaches. Common adverse reactions reported with the use of oral bumetanide include muscle cramps, dizziness, hypotension, nausea and encephalopathy (in patients with pre-existing liver disease).

Please see full Prescribing Information for ENBUMYST.

References: 1. ENBUMYST. Prescribing Information. Corstasis Therapeutics. 2. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol. 2001;53:3-21.

INDICATION

ENBUMYST is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome in adults.

IMPORTANT SAFETY INFORMATION

    • ENBUMYST is contraindicated in patients with anuria, hepatic coma, or a history of hypersensitivity to bumetanide, including anaphylaxis and anaphylactoid reactions.
    • ENBUMYST is a diuretic that may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, those with inadequate electrolyte intake, and the elderly. Abnormalities may include changes in blood electrolytes, BUN, glucose, and uric acid. Monitor serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid frequently during therapy.
    • Bumetanide can cause dehydration and azotemia. Discontinue bumetanide if azotemia worsens and oliguria occurs during treatment of severe progressive renal disease.
    • Tinnitus and hearing loss (usually reversible) have been reported with loop diuretics, including bumetanide. Reports indicate that ototoxicity is associated with rapid injection, severe renal impairment, use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
    • Due to potential altered absorption, avoid use in patients with significant nasal mucosal or structural abnormalities, such as acute episodes of rhinitis or congestion due to any cause.
    • Advise lactating women treated with ENBUMYST to monitor their breastfed infants for excessive urine output, dehydration, and lethargy.
    • Most common adverse reactions reported in ENBUMYST studies were hypovolemia and headaches. Common adverse reactions reported with the use of oral bumetanide include muscle cramps, dizziness, hypotension, nausea and encephalopathy (in patients with pre-existing liver disease).

Please see full Prescribing Information for ENBUMYST.